Top

Cardiovascular Diabetology

Published in:

Open Access 01-12-2023 | Acute Kidney Injury | Research

Long- and very long-chain ceramides are predictors of acute kidney injury in patients with acute coronary syndrome: the PEACP study

Authors: Lianjing Liang, Dongze Li, Rui Zeng, Haihong Zhang, Lin Lv, Wei Wei, Zhi Wan

Published in: Cardiovascular Diabetology | Issue 1/2023

Abstract

Background

Acute kidney injury (AKI) can be caused by multiple factors/events, including acute coronary syndrome (ACS). Ceramides are involved in atherosclerosis progression, cardiovascular events, and renal damage. Almost no studies have been conducted on the relationship between ceramide concentrations and AKI events. Therefore, we evaluated the association between plasma ceramide level at admission and AKI in patients with ACS undergoing percutaneous coronary intervention.

Methods

We enrolled 842 ACS patients from the Prospective Multicenter Study for Early Evaluation of Acute Chest Pain. AKI was defined using the criteria from the 2012 Kidney Disease: Improving Global Outcomes. Eleven C16–C26 ceramides were measured using the high-performance liquid chromatography interfaced to tandem mass spectrometer procedure. Logistic regression models were used to evaluate relationships between ceramides and AKI risk. The area under the receiver operating characteristic curves (AUC) was used to evaluate differences between ceramides.

Results

Overall, 139 (16.5%) patients developed AKI during hospitalisation. Patients who developed AKI had higher levels of Cer(d18:1/16:0), Cer(d18:1/18:0), Cer(d18:1/20:0), Cer(d18:1/21:0), Cer(d18:1/24:1), and Cer(d18:1/24:2) than patients who did not (P < 0.05). In risk-factor adjusted logistic regression models, these ceramides were independently associated with AKI risk (P < 0.05). Cer(d18:1/24:2) had the highest odds ratio of 3.503 (Q4 vs. Q1, 95% confidence interval: 1.743–7.040, P < 0.001). Ceramides had AUCs of 0.581–0.661 (P < 0.001) for AKI. Each ceramide combined with the Mehran risk score (AUC: 0.780) had AUCs of 0.802–0.808, greater than the Mehran risk score alone.

Conclusion

Long-chain and very-long-chain ceramide levels may help determine the high AKI risk beyond traditional assessments.

Available only for authorised users

Marenzi G, Cosentino N, Bartorelli AL. Acute kidney injury in patients with acute coronary syndromes. Heart. 2015;101(22):1778–85.PubMedCrossRef

Marenzi G, Cabiati A, Bertoli SV, Assanelli E, Marana I, De Metrio M, Rubino M, Moltrasio M, Grazi M, Campodonico J, et al. Incidence and relevance of acute kidney injury in patients hospitalized with acute coronary syndromes. Am J Cardiol. 2013;111(6):816–22.PubMedCrossRef

Goldberg A, Hammerman H, Petcherski S, Zdorovyak A, Yalonetsky S, Kapeliovich M, Agmon Y, Markiewicz W, Aronson D. Inhospital and 1-year mortality of patients who develop worsening renal function following acute ST-elevation myocardial infarction. Am Heart J. 2005;150(2):330–7.PubMedCrossRef

Kaltsas E, Chalikias G, Tziakas D. The incidence and the prognostic impact of acute kidney injury in acute myocardial infarction patients: current preventive strategies. Cardiovasc Drugs Ther. 2018;32(1):81–98.PubMedCrossRef

Marenzi G, Assanelli E, Campodonico J, De Metrio M, Lauri G, Marana I, Moltrasio M, Rubino M, Veglia F, Montorsi P, et al. Acute kidney injury in ST-segment elevation acute myocardial infarction complicated by cardiogenic shock at admission. Crit Care Med. 2010;38(2):438–44.PubMedCrossRef

Gault CR, Obeid LM, Hannun YA. An overview of sphingolipid metabolism: from synthesis to breakdown. Adv Exp Med Biol. 2010;688:1–23.PubMedPubMedCentralCrossRef

Anroedh S, Hilvo M, Akkerhuis KM, Kauhanen D, Koistinen K, Oemrawsingh R, Serruys P, van Geuns RJ, Boersma E, Laaksonen R, et al. Plasma concentrations of molecular lipid species predict long-term clinical outcome in coronary artery disease patients. J Lipid Res. 2018;59(9):1729–37.PubMedPubMedCentralCrossRef

Cheng JM, Suoniemi M, Kardys I, Vihervaara T, de Boer SP, Akkerhuis KM, Sysi-Aho M, Ekroos K, Garcia-Garcia HM, Oemrawsingh RM, et al. Plasma concentrations of molecular lipid species in relation to coronary plaque characteristics and cardiovascular outcome: results of the ATHEROREMO-IVUS study. Atherosclerosis. 2015;243(2):560–6.PubMedCrossRef

Laaksonen R, Ekroos K, Sysi-Aho M, Hilvo M, Vihervaara T, Kauhanen D, Suoniemi M, Hurme R, März W, Scharnagl H, et al. Plasma ceramides predict cardiovascular death in patients with stable coronary artery disease and acute coronary syndromes beyond LDL-cholesterol. Eur Heart J. 2016;37(25):1967–76.PubMedPubMedCentralCrossRef

10.

Tu C, Xie L, Wang Z, Zhang L, Wu H, Ni W, Li C, Li L, Zeng Y. Association between ceramides and coronary artery stenosis in patients with coronary artery disease. Lipids Health Dis. 2020;19(1):151.PubMedPubMedCentralCrossRef

11.

Peterson LR, Xanthakis V, Duncan MS, Gross S, Friedrich N, Volzke H, Felix SB, Jiang H, Sidhu R, Nauck M, et al. Ceramide remodeling and risk of cardiovascular events and mortality. J Am Heart Assoc. 2018. https://doi.org/10.1161/JAHA.117.007931.CrossRefPubMedPubMedCentral

12.

Tarasov K, Ekroos K, Suoniemi M, Kauhanen D, Sylvänne T, Hurme R, Gouni-Berthold I, Berthold HK, Kleber ME, Laaksonen R, et al. Molecular lipids identify cardiovascular risk and are efficiently lowered by simvastatin and PCSK9 deficiency. J Clin Endocrinol Metab. 2014;99(1):E45-52.PubMedCrossRef

13.

Nwabuo CC, Duncan M, Xanthakis V, Peterson LR, Mitchell GF, McManus D, Cheng S, Vasan RS. Association of circulating ceramides with cardiac structure and function in the community: the framingham heart study. J Am Heart Assoc. 2019;8(19):e013050.PubMedPubMedCentralCrossRef

14.

Li PL, Zhang Y. Cross talk between ceramide and redox signaling: implications for endothelial dysfunction and renal disease. Handb Exp Pharmacol. 2013;216:171–97.CrossRef

15.

Basnakian AG, Ueda N, Hong X, Galitovsky VE, Yin X, Shah SV. Ceramide synthase is essential for endonuclease-mediated death of renal tubular epithelial cells induced by hypoxia-reoxygenation. Am J Physiol Renal Physiol. 2005;288(2):F308-314.PubMedCrossRef

16.

Ueda N. Ceramide-induced apoptosis in renal tubular cells: a role of mitochondria and sphingosine-1-phoshate. Int J Mol Sci. 2015;16(3):5076–124.PubMedPubMedCentralCrossRef

17.

Ostermann M, Liu K. Pathophysiology of AKI. Best Pract Res Clin Anaesthesiol. 2017;31(3):305–14.PubMedCrossRef

18.

Raichur S, Brunner B, Bielohuby M, Hansen G, Pfenninger A, Wang B, Bruning JC, Larsen PJ, Tennagels N. The role of C16:0 ceramide in the development of obesity and type 2 diabetes: CerS6 inhibition as a novel therapeutic approach. Mol Metab. 2019;21:36–50.PubMedPubMedCentralCrossRef

19.

Turpin SM, Nicholls HT, Willmes DM, Mourier A, Brodesser S, Wunderlich CM, Mauer J, Xu E, Hammerschmidt P, Bronneke HS, et al. Obesity-induced CerS6-dependent C16:0 ceramide production promotes weight gain and glucose intolerance. Cell Metab. 2014;20(4):678–86.PubMedCrossRef

20.

Fekry B, Jeffries KA, Esmaeilniakooshkghazi A, Ogretmen B, Krupenko SA, Krupenko NI. CerS6 is a novel transcriptional target of p53 protein activated by non-genotoxic stress. J Biol Chem. 2016;291(32):16586–96.PubMedPubMedCentralCrossRef

21.

Yacoub A, Hamed HA, Allegood J, Mitchell C, Spiegel S, Lesniak MS, Ogretmen B, Dash R, Sarkar D, Broaddus WC, et al. PERK-dependent regulation of ceramide synthase 6 and thioredoxin play a key role in mda-7/IL-24-induced killing of primary human glioblastoma multiforme cells. Cancer Res. 2010;70(3):1120–9.PubMedPubMedCentralCrossRef

22.

Eberle M, Ebel P, Wegner MS, Mannich J, Tafferner N, Ferreiros N, Birod K, Schreiber Y, Krishnamoorthy G, Willecke K, et al. Regulation of ceramide synthase 6 in a spontaneous experimental autoimmune encephalomyelitis model is sex dependent. Biochem Pharmacol. 2014;92(2):326–35.PubMedCrossRef

23.

Bai X, He T, Liu M, Li L, Chen J, Cao M, Liu Y, Yang C, Jia W, Tao K, et al. Integrative analysis of MicroRNAs and mRNAs in LPS-induced macrophage inflammation based on adipose tissue stem cell therapy. Inflammation. 2021;44(1):407–20.PubMedCrossRef

24.

Hernandez-Corbacho MJ, Canals D, Adada MM, Liu M, Senkal CE, Yi JK, Mao C, Luberto C, Hannun YA, Obeid LM. Tumor Necrosis Factor-alpha (TNFalpha)-induced ceramide generation via ceramide synthases regulates loss of Focal Adhesion Kinase (FAK) and programmed cell death. J Biol Chem. 2015;290(42):25356–73.PubMedPubMedCentralCrossRef

25.

Kim YR, Lee EJ, Shin KO, Kim MH, Pewzner-Jung Y, Lee YM, Park JW, Futerman AH, Park WJ. Hepatic triglyceride accumulation via endoplasmic reticulum stress-induced SREBP-1 activation is regulated by ceramide synthases. Exp Mol Med. 2019;51(11):1–16.PubMedPubMedCentral

26.

Stiban J, Perera M. Very long chain ceramides interfere with C16-ceramide-induced channel formation: a plausible mechanism for regulating the initiation of intrinsic apoptosis. Biochim Biophys Acta. 2015;1848(2):561–7.PubMedCrossRef

27.

Nicholson RJ, Pezzolesi MG, Summers SA. Rotten to the cortex: ceramide-mediated lipotoxicity in diabetic kidney disease. Front Endocrinol (Lausanne). 2020;11:622692.PubMedCrossRef

28.

Mantovani A, Lunardi G, Bonapace S, Dugo C, Altomari A, Molon G, Conti A, Bovo C, Laaksonen R, Byrne CD, et al. Association between increased plasma ceramides and chronic kidney disease in patients with and without ischemic heart disease. Diabetes Metab. 2021;47(1):101152.PubMedCrossRef

29.

Mitsnefes M, Scherer PE, Friedman LA, Gordillo R, Furth S, Warady BA. Ceramides and cardiac function in children with chronic kidney disease. Pediatric Nephrol (Berlin, Germany). 2014;29(3):415–22.CrossRef

30.

Ichi I, Kamikawa C, Nakagawa T, Kobayashi K, Kataoka R, Nagata E, Kitamura Y, Nakazaki C, Matsura T, Kojo S. Neutral sphingomyelinase-induced ceramide accumulation by oxidative stress during carbon tetrachloride intoxication. Toxicology. 2009;261(1–2):33–40.PubMedCrossRef

31.

Amsterdam EA, Wenger NK, Brindis RG, Casey DE Jr, Ganiats TG, Holmes DR Jr, Jaffe AS, Jneid H, Kelly RF, Kontos MC, et al. 2014 AHA/ACC guideline for the management of patients with Non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. J Am Coll Cardiol. 2014;64(24):e139–228.PubMedCrossRef

32.

O’Gara PT, Kushner FG, Ascheim DD, Casey DE Jr, Chung MK, de Lemos JA, Ettinger SM, Fang JC, Fesmire FM, Franklin BA, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;61(4):e78–140.PubMedCrossRef

33.

Granger CB, Goldberg RJ, Dabbous O, Pieper KS, Eagle KA, Cannon CP, Van De Werf F, Avezum A, Goodman SG, Flather MD, et al. Predictors of hospital mortality in the global registry of acute coronary events. Arch Intern Med. 2003;163(19):2345–53.PubMedCrossRef

34.

Gensini GG. A more meaningful scoring system for determining the severity of coronary heart disease. Am J Cardiol. 1983;51(3):606.PubMedCrossRef

35.

Jia Y, Gao Y, Li D, Cao Y, Cheng Y, Li F, Xiao L, Jiang Y, Wan Z, Zeng Z, et al. Geriatric nutritional risk index score predicts clinical outcome in patients with acute ST-segment elevation myocardial infarction. J Cardiovasc Nurs. 2020;35(6):E44-e52.PubMedCrossRef

36.

Jia Y, Li H, Li D, Li F, Li Q, Jiang Y, Gao Y, Wan Z, Cao Y, Zeng Z, et al. Prognostic value of Braden scale in patients with acute myocardial infarction: from the retrospective multicenter study for early evaluation of acute chest pain. J Cardiovasc Nurs. 2020;35(6):E53-e61.PubMedCrossRef

37.

Mehran R, Aymong ED, Nikolsky E, Lasic Z, Iakovou I, Fahy M, Mintz GS, Lansky AJ, Moses JW, Stone GW, et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol. 2004;44(7):1393–9.PubMed

38.

Section 2: AKI Definition. Kidney international supplements 2012;2(1):19–36. https://doi.org/10.1038/kisup.2011.32

39.

Sarafian MH, Gaudin M, Lewis MR, Martin FP, Holmes E, Nicholson JK, Dumas ME. Objective set of criteria for optimization of sample preparation procedures for ultra-high throughput untargeted blood plasma lipid profiling by ultra performance liquid chromatography-mass spectrometry. Anal Chem. 2014;86(12):5766–74.PubMedCrossRef

40.

Huang Q, Hao S, Yao X, You J, Li X, Lai D, Han C, Schilling J, Hwa KY, Thyparambil S, et al. High-throughput quantitation of serological ceramides/dihydroceramides by LC/MS/MS: pregnancy baseline biomarkers and potential metabolic messengers. J Pharm Biomed Anal. 2021;192:113639.PubMedCrossRef

41.

Pickering JW, Blunt IRH, Than MP. Acute kidney injury and mortality prognosis in acute coronary syndrome patients: a meta-analysis. Nephrology (Carlton). 2018;23(3):237–46.PubMedCrossRef

42.

Yu J, Li D, Jia Y, Li F, Jiang Y, Zhang Q, Gao Y, Liao X, Zeng R, Wan Z. Nutritional risk screening 2002 was associated with acute kidney injury and mortality in patients with acute coronary syndrome: Insight from the REACP study. Nutr Metab Cardiovasc Dis. 2021;31(4):1121–8.PubMedCrossRef

43.

Gencer B, Morrow DA, Braunwald E, Goodrich EL, Hilvo M, Kauhanen D, Sabatine MS, Laaksonen R, O’Donoghue ML. Plasma ceramide and phospholipid-based risk score and the risk of cardiovascular death in patients after acute coronary syndrome. Eur J Prev Cardiol. 2020. https://doi.org/10.1093/eurjpc/zwaa143.CrossRefPubMed

44.

Yao K, Wang Y, Xu D, Liu X, Shen C, Hu W, Wang Z, Wu R, Tang X, Sun A, et al. Effect of combined testing of ceramides with high-sensitive troponin T on the detection of acute coronary syndrome in patients with chest pain in China: a prospective observational study. BMJ Open. 2019;9(7):e028211.PubMedPubMedCentralCrossRef

45.

Abellás-Sequeiros RA, Raposeiras-Roubín S, Abu-Assi E, González-Salvado V, Iglesias-Álvarez D, Redondo-Diéguez A, González-Ferreiro R, Ocaranza-Sánchez R, Peña-Gil C, García-Acuña JM, et al. Mehran contrast nephropathy risk score: Is it still useful 10 years later? J Cardiol. 2016;67(3):262–7.PubMedCrossRef

46.

Koowattanatianchai S, Chantadansuwan T, Kaladee A, Phinyo P, Patumanond J. Practical risk stratification score for prediction of contrast-induced nephropathy after primary percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction. Cardiol Res. 2019;10(6):350–7.PubMedPubMedCentralCrossRef

47.

Rodriguez F, Bonacasa B, Fenoy FJ, Salom MG. Reactive oxygen and nitrogen species in the renal ischemia/reperfusion injury. Curr Pharm Des. 2013;19(15):2776–94.PubMedCrossRef

48.

Ueda N, Camargo SMR, Hong X, Basnakian AG, Walker PD, Shah SV. Role of ceramide synthase in oxidant injury to renal tubular epithelial cells. J Am Soc Nephrol. 2001;12(11):2384–91.PubMedCrossRef

49.

Kalhorn T, Zager RA. Renal cortical ceramide patterns during ischemic and toxic injury: assessments by HPLC-mass spectrometry. Am J Physiol. 1999;277(5):F723-733.PubMed

50.

Bergman BC, Brozinick JT, Strauss A, Bacon S, Kerege A, Bui HH, Sanders P, Siddall P, Kuo MS, Perreault L. Serum sphingolipids: relationships to insulin sensitivity and changes with exercise in humans. Am J Physiol Endocrinol Metab. 2015;309(4):E398-408.PubMedPubMedCentralCrossRef

51.

Couto SMF, Machado DI, Conde C, Silva VC, Souza AA, Peres KB, Brandi BA, Vattimo MFF. Physical training is a potential modifier of risk for contrast-induced acute kidney injury in diabetes mellitus. Biomed Res Int. 2020;2020:1830934.PubMedPubMedCentralCrossRef

52.

Pistolesi V, Regolisti G, Morabito S, Gandolfini I, Corrado S, Piotti G, Fiaccadori E. Contrast medium induced acute kidney injury: a narrative review. J Nephrol. 2018;31(6):797–812.PubMedCrossRef

Title: Long- and very long-chain ceramides are predictors of acute kidney injury in patients with acute coronary syndrome: the PEACP study
Authors: Lianjing Liang
Dongze Li
Rui Zeng
Haihong Zhang
Lin Lv
Wei Wei
Zhi Wan
Publication date: 01-12-2023
Publisher: BioMed Central
Keywords: Acute Kidney Injury
Acute Coronary Syndrome
Acute Kidney Injury
Published in: Cardiovascular Diabetology / Issue 1/2023
Electronic ISSN: 1475-2840
DOI: https://doi.org/10.1186/s12933-023-01831-6

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2023

Roles of gut microbiota in atrial fibrillation: insights from Mendelian randomization analysis and genetic data from over 430,000 cohort study participants

Effects of exenatide on coronary stent’s endothelialization in subjects with type 2 diabetes: a randomized controlled trial. The Rebuild study

Glycemic control, HbA1c variability, and major cardiovascular adverse outcomes in type 2 diabetes patients with elevated cardiovascular risk: insights from the ACCORD study

Glycemic variability and in-hospital death of critically ill patients and the role of ventricular arrhythmias

Combining glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) in patients with type 2 diabetes mellitus (T2DM)

Cardiovascular mortality in patients with advanced chronic kidney disease with and without diabetes: a nationwide cohort study

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials